• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Tumor Markers
You are here: Product Lines > Bone Metabolism > Tumor Markers
Toolbar - View Selection
 
 Items 1-20 of 52 Page 1 of 3 Select Page: 1 2 3  >>  
ALX-850-270 Revised 15-Feb-07
M30-Apoptosense® ELISA Kit
Add to Clipboard
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY Cytokeratin-based Apoptosis Detection
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-850-270-KI01 (CE Mark) 1 Kit Inquire
ALX-850-270-5001 (CE Mark) 5x1 Kit Inquire
Product Specification
APPLICATION: For the specific and sensitive detection of caspase-cleaved intermediate filament protein cytokeratin-18 (CK18Asp396-NE: M30 neo-epitope). The M30-Apoptosense® ELISA is primarely intended for quantitative determination of epithelial apoptosis in cytosolic cell extracts or cell culture supernatants, human serum or plasma or other body fluids.
Use in combination with the M65® ELISA Kit (Prod. No. ALX-850-310) to allow the calculation of apoptosis:necrosis ratios.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Do not freeze.
Product Specific Literature References
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis: M.P. Leers, et al.; J. Pathol. 187, 567 (1999) Abstract
Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner: A. Mandic, et al.; Mol. Cell. Biol. 21, 3684 (2001) Abstract
An immunohistochemical study of the clearance of apoptotic cellular fragments: M.P. Leers, et al.; Cell. Mol. Life Sci. 59, 1358 (2002) Abstract
A novel high-through-put assay for screening of pro-apoptotic drugs: M. Hagg, et al.; Invest. New Drugs 20, 253 (2002) Abstract
Measurement of an apoptotic product in the sera of breast cancer patients: T. Ueno, et al.; Eur. J. Cancer 39, 769 (2003) Abstract
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera: K. Biven, et al.; Apoptosis 8, 263 (2003) Abstract
Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells: D. Thurnher, et al.; Head and Neck 25, 732 (2003) Abstract
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18: G. Kramer, et al.; Cancer Res. 64, 1751 (2004) Abstract
Keratin 8/18 breakdown and reorganization during apoptosis: B. Schutte, et al.; Exp. Cell Res. 297, 11 (2004) Abstract
Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP: J. Cummings, et al.; Br. J. Cancer 92, 532 (2005) Abstract
Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C: B. Kronenberger, et al.; J. Viral Hepat. 12, 307 (2005) Abstract
Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas: P. Luciani, et al.; J. Clin. Endocrinol. Metab. 90, 6156 (2005) Abstract; Full Text
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum: N. Seidel, et al.; Hepatology 42, 113 (2005) Abstract
For an extensive and regularly updated literature list, please click here.:
General Information
BACKGROUND/TECHNICAL INFORMATION

Cytokeratin-18 expression has been shown in but is not limited to cells and tissues from lung, breast, intestine, gut, colon, kidney, pancreas, bladder, trophoblasts.
The M30‑Apoptosense® ELISA uses the well-established M30 CytoDEATH monoclonal antibody which has been shown in numerous independent studies to be specific to the CK18 Asp396 caspase cleavage site and represents a validated apoptosis marker that does not react with viable or necrotic cells.

Apoptosis detection using M30 CytoDEATH has been described in several publications to serve as a superior technique compared to TUNEL or detection of gammaH2AX phosphorylation. Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo‑stressed colonic mucosa under conditions of DNA-damage may be repaired and results in false-positive counts of apoptotic cells. In addition has modest or transient caspase activation without the cleavage of death substrates been attributed to non-suicidal processes such as proliferation, differentiation and inflammation.

The unmatched sensitivity and superior performance characteristics of M30‑Apoptosense® ELISA even allows the tracing of apoptotic epithelial cells (e.g. carcinoma cells) in human blood samples as no contribution comes from apoptotic inflammatory lymphoid cells as those belong -together with neuronal cells and tissues- to the prominent populations of Cytokeratin-18 negative cells.

By measuring the caspase-cleaved Cytokeratin-18 with M30 one can selectively quantify the extent of non-lympoid e.g. epithelial carcinoma target cells in natural killer (NK) activity tests in one well containing a mixed cell population of otherwise un-labeled effector (T cells: CK18 and M30 negative) and target cells (carcinoma cells: CK18 and M30 positive).

As the principle of the M30‑Apoptosense® ELISA is based upon measuring the rapid accumulation of a caspase cleavage product -that is comparably stable- rather than proteolytic activity itself, it is recommended as an advantageous assay for high through‑put screening (HTS) selective for pro-apoptotic compounds:
- It avoids the necessity to analyse multiple time‑points after the apoptotic stimulus as it has the broadest time-window for optimal signal strength compared to alternative apoptosis detection methods as it does not rely on cell proliferation M30‑Apoptosense® ELISA avoids false positive counts due to cell cycle arrest, senescence or differentiation.
- For mechanistically studies the optional analysis of only the cell culture supernatant avoiding cell lysis allows the ongoing manipulation of the cells to study sensitization or synergistic effects of different stimuli (e.g. drugs) in the same tissue culture well.

Please also see our Product Flyer "M30 CytoDEATH™ - Key Marker to Detect Apoptosis in Epithelial Cells" and the Original Manufacturer’s Product Description.
MANUFACTURER Manufactured by Peviva AB.
Related Products
Further Categories Containing This Product:
Tumor Markers • ELISA & EIA Kits
 
 
ALX-804-590 Revised 27-Nov-08
M30 CytoDEATH™ Monoclonal Antibody
Add to Clipboard
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY Cytokeratin-based Apoptosis Detection
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-590-T200   200 tests 465.00 USD Add To Cart
ALX-804-590B-T200 Biotin 200 tests 495.00 USD Add To Cart
ALX-804-590F-T200 FITC 200 tests 495.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Monkey
Others
CLONE: M30
ISOTYPE: Mouse IgG2b
CONCENTRATION: M30 & M30-FITC: 0.1mg/ml
M30-Biotin: 0.5mg/ml
FORMULATION: Liquid. In 200μl PBS containing 0.1% BSA, PEG, sucrose and 0.09% sodium azide.
IMMUNOGEN: CK18 (cytokeratin 18) fragments purified from supernatant from human carcinoma cell line WiDr CCL218.
SPECIFICITY: Recognizes the CK18-Asp396 neo-epitope (M30) on human, monkey and bovine caspase-cleaved CK18. Does not cross-react with intact CK18.
APPLICATION: M30 & M30-Biotin:
Flow Cytometry
Immunocytochemistry
Immunohistochemistry (frozen sections; paraffin sections)
Western Blot

M30-FITC:
Flow Cytometry
Immunocytochemistry

A dilution of 1:100 in incubation buffer is generally recommended. Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis: M.P. Leers, et al.; J. Pathol. 187, 567 (1999) Abstract
Apoptosis of circulating tumor cells in prostate cancer patients: C. J. Larson, et al.; Cytometry A. 62, 46 (2004) Abstract
Uncovering the roles of intermediate filaments in apoptosis: N. Marceau; Methods Cell Biol. 78, 95 (2004) Abstract
Maternal smoking, intrauterine growth restriction, and placental apoptosis: C. Vogt Isaksen; Pediatr. Dev. Pathol. 7, 433 (2004) Abstract
Modular effects of estradiol on ethanol-induced apoptosis in human intestinal epithelial cells: K. Asai, et al.; Scand. J. Gastroenterol. 40, 326 (2005) Abstract
Apoptosis resistance in Barrett’s esophagus: ex vivo bioassay of live stressed tissues: K. Dvorakova, et al.; Am. J. Gastroenterol. 100, 424 (2005) Abstract
Oncosis represents the main type of cell death in mouse models of cholestasis: P. Fickert, et al.; J. Hepatol. 42, 378 (2005) Abstract
Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: a differential expression study: P.Y. Fong, et al.; Cancer 103, 268 (2005) Abstract
Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo-stressed colonic mucosa: H. Holubec, et al.; J. Histochem. Cytochem. 53, 229 (2005) Abstract
Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma: I. Kausch, et al.; Eur. Urol. 47, 703 (2005) Abstract
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: Potential targets for apoptosis induction: J.J. Koornstra, et al.; Eur. J. Cancer 41, 1195 (2005) Abstract
Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: possible implications in the process of trophoblast apoptosis: H. Lee, et al.; Placenta 26, 226 (2005) Abstract
Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability: C. Miquel, et al.; Am. J. Clin. Pathol. 123, 562 (2005) Abstract
Fas ligand expression by maternal decidual cells is negatively correlated with the abundance of leukocytes present at the maternal-fetal interface: Q. Qiu, et al.; J. Reprod. Immunol. 65, 121 (2005) Abstract
Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis: N. Vigneswaran, et al.; Int. J. Oncol. 26, 103 (2005) Abstract
Effects of vitamin restriction and supplementation on rat intestinal epithelial cell apoptosis: B. Vijayalakshmi, et al.; Free Radic. Biol. Med. 38, 1614 (2005) Abstract
Expression levels of Akt in nimesulide-treated squamous carcinoma cell lines of the head and neck: L. Vormittag, et al.; Oncol. Rep. 13, 207 (2005) Abstract
For a comprehensive bibliography please click here:
General Information
BACKGROUND/TECHNICAL INFORMATION Cytokeratin 18 expression has been shown in but is not limited to cells and tissues from lung, breast, intestine, gut, colon, kidney, pancreas, bladder, trophoblasts ... etc.
The M30 CytoDEATH™ monoclonal antibody has been shown in numerous independent studies to be specific to the CK18-Asp396 caspase cleavage site (neo-epitope (M30)) and represents a well-established, validated apoptosis marker that does not react with viable or necrotic cells.
M30 CytoDEATH™ detects human, monkey and bovine apoptotic epithelial cells and tissues and has been validated for many applications including immunohistochemistry of formalin-fixed paraffin-embedded (FFPE) tissues.
Apoptosis detection using M30 CytoDEATH™ has been described in several publications to serve as a superior technique compared to TUNEL or detection of γH2AX phosphorylation. Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo‑stressed colonic mucosa under conditions of DNA-damage may be repaired and results in false-positive counts of apoptotic cells. In addition has modest or transient caspase activation without the cleavage of death substrates been attributed to non-suicidal processes such as proliferation, differentiation and inflammation.

For more information on procedures and materials required please see also the Original Manufacturers Product Description
(click here to download pdf for M30 CytoDEATH™ Monoclonal Antibody)
(click here to download pdf for M30 CytoDEATH™ Monoclonal Antibody (Biotin))
(click here to download pdf for M30 CytoDEATH™ Monoclonal Antibody (FITC))
MANUFACTURER Manufactured by Peviva AB.
Related Products
Further Categories Containing This Product:
Monoclonal Antibodies • Tumor Markers
 
 
ALX-850-310 Revised 04-Jul-08
M65® ELISA Kit
Add to Clipboard
PRODUCT LINE Cell Death / Apoptosis / Autophagy
PRODUCT CATEGORY Cytokeratin-based Apoptosis Detection
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-850-310-KI01 (CE Mark) 1 Kit Inquire
Product Specification
APPLICATION: For the specific and sensitive detection of soluble CK18 (cytokeratin 18). The M65® ELISA is primarily intended for quantitative determination of total cell death (apoptosis and necrosis) of CK18-positive cells (e.g. carcinoma) in human serum and plasma samples.
Use in combination with the M30-Apoptosense® ELISA Kit (Prod. No. ALX-850-270) to allow the calculation of apoptosis:necrosis ratios.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Do not freeze.
Product Specific Literature References
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18: G. Kramer, et al.; Cancer Res. 64, 1751 (2004) Abstract
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker: S. Linder, et al.; Cancer Lett. 214, 1 (2004) Abstract
Apoptosis pathway-targeted drugs--from the bench to the clinic: J. Cummings, et al; Biochim. Biophys. Acta 1705, 53 (2004) Abstract
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis: H. Erdal, et al.; PNAS 102, 192 (2005) Abstract
General Information
BACKGROUND/TECHNICAL INFORMATION Please also see our Product Flyer "M30 CytoDEATH™ - Key Marker to Detect Apoptosis in Epithelial Cells" (click here to download pdf) and the Original Manufacturer’s Product Description.
MANUFACTURER Manufactured by Peviva AB.
Related Products
Further Categories Containing This Product:
Tumor Markers • ELISA & EIA Kits
 
 
ALX-801-077 Revised 15-Jan-08
Monoclonal Antibody to 90K/Mac-2 BP (human) (SP-2)
Add to Clipboard
PRODUCT LINE Cancer
PRODUCT CATEGORY Tumor Markers
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-077-C100   100 µg 259.00 USD Add To Cart
ALX-801-077F-T100 FITC 100 tests 308.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: SP-2
ISOTYPE: Mouse IgG1
PURITY: ≥95% (SDS-PAGE)
FORMULATION: SP-2: Liquid. 0.1mg/ml in PBS.
SP-2-FITC: Liquid. 100 tests in 1ml 50mM TRIS, pH 7.4, containing 100mM NaCl, 1% BSA and 0.02% sodium azide.
IMMUNOGEN: Human 90K/Mac-2 BP.
SPECIFICITY: Recognizes the Mac-2 mucin-like binding domain of human 90K/Mac-2 BP.
APPLICATION: Immunohistochemistry (acetone fixed frozen sections, paraffin sections, cell smears (5µg/ml))
Western Blot (non-denaturating conditions)
Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: +4°C
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Product Specific Literature References
Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines: S. Iacobelli, et al.; FEBS Lett. 319, 59 (1993) Abstract
The secreted tumor-associated antigen 90K is a potent immune stimulator: A. Ullrich, et al.; J. Biol. Chem. 269, 18401 (1994) Abstract; Full Text
Further Categories Containing This Product:
Monoclonal Antibodies
 
 
ALX-804-097 Revised 10-Oct-06
Monoclonal Antibody to Androgen Receptor (AN1-15)
Add to Clipboard
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY Androgens & Androgen Receptors / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-097-C050   50 µg 379.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
Rat
Monkey
CLONE: AN1-15
ISOTYPE: Rat IgG
FORMULATION: Lyophilized from purified antibody in PBS.
RECONSTITUTION: Reconstitute with PBS.
IMMUNOGEN: 241 aa (331-572) fusion protein derived from human androgen receptor.
SPECIFICITY: Recognizes human, mouse, rat and monkey androgen receptor. Detects a band of ~110kDa by Western blot.
APPLICATION: Immunocytochemistry (5µg/ml)
Immunohistochemistry (frozen sections, paraffin sections (4µg/ml))
Immunoprecipitation
Western Blot (1µg/ml)
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
Product Images
Please click on thumbnails to enlarge.
Further Categories Containing This Product:
Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-036 Revised 15-Oct-07
Monoclonal Antibody to Breast Cancer Resistance Protein (BXP-53)
Add to Clipboard
SYNONYMS anti-BCRP MAb (BXP-53)
anti-MXR MAb (BXP-53)
anti-ABCG2 MAb (BXP-53)
anti-CD338 MAb (BXP-53)
PRODUCT LINE Cancer
PRODUCT CATEGORY Breast Cancer Resistance Protein [BCRP / MXR] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-036-C125   125 µg 350.00 USD Add To Cart
ALX-801-036-C250   250 µg 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
CLONE: BXP-53
ISOTYPE: Rat IgG2a
CONCENTRATION: ~250µg/ml
FORMULATION: Liquid. In serum free cell culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN: Recombinant mouse BCRP (breast cancer resistance protein; MXR) (aa 221-394).
SPECIFICITY: Recognizes an internal epitope of human and mouse BCRP.
APPLICATION: Immunocytochemistry: Use 1:20-1:50 dilution on acetone fixed cytospin preparations.
Immunohistochemistry (frozen sections, paraffin sections): Use 1:20 on acetone fixed frozen sections followed by incubation with biotin-labelled rabbit anti-rat IgG and HRP-labelled streptavidin.
For paraffin sections see [1].
Western Blot: Use 1:20-1:50 dilution and  HRP-labelled anti-rat IgG.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
Product Specific Literature References
[1] The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria: J.W. Jonker, et al.; PNAS 99, 15649 (2002) Abstract; Full Text
Further Categories Containing This Product:
Monoclonal Antibodies • Tumor Markers • CD Antibodies
 
 
ALX-801-029 Revised 15-Oct-07
Monoclonal Antibody to Breast Cancer Resistance Protein (human) (BXP-21)
Add to Clipboard
SYNONYMS anti-BCRP (human) MAb (BXP-21)
anti-MXR (human) MAb (BXP-21)
anti-ABCG2 (human) MAb (BXP-21)
anti-CD338 (human) MAb (BXP-21)
PRODUCT LINE Cancer
PRODUCT CATEGORY Breast Cancer Resistance Protein [BCRP / MXR] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-029-C125   125 µg 350.00 USD Add To Cart
ALX-801-029-C250   250 µg 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: BXP-21
ISOTYPE: Mouse IgG2a
CONCENTRATION: ~250µg/ml
FORMULATION: Liquid. In serum free cell culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN: Recombinant human BCRP (breast cancer resistance protein; MXR) (aa 271-396).
SPECIFICITY: Recognizes an internal epitope of human BCRP. Does not cross-react with human P-glycoprotein, MRP1 or MRP2.
APPLICATION: Immunocytochemistry: Use 1:20-1:50 dilution on acetone fixed cytospin preparations.
Immunohistochemistry:
Frozen sections: Use 1:20 dilution on acetone fixed frozen sections followed by incubation with rabbit anti-mouse IgG and a monoclonal mouse APAAP complex.
Paraffin sections: Use on formaldehyde-fixed paraffin-embedded human tissues and tumors after pretreatment with 10mM citric acid, pH 6.0, for 20 min.
Western Blot
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
Product Specific Literature References
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues: M. Maliepaard, et al.; Cancer Res. 61, 3458 (2001) Abstract; Full Text
Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter : C. Özvegy, et al.; J. Biol. Chem. 277, 47980 (2002) Abstract; Full Text
General Literature References
A multidrug resistance transporter from human MCF-7 breast cancer cells: L.A. Doyle, et al.; PNAS 95, 15665 (1998) Abstract; Full Text
Further Categories Containing This Product:
Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-027 Revised 15-Oct-07
Monoclonal Antibody to Breast Cancer Resistance Protein (human) (BXP-34)
Add to Clipboard
SYNONYMS anti-BCRP (human) MAb (BXP-34)
anti-MXR (human) MAb (BXP-34)
anti-ABCG2 (human) MAb (BXP-34)
anti-CD338 (human) MAb (BXP-34)
PRODUCT LINE Cancer
PRODUCT CATEGORY Breast Cancer Resistance Protein [BCRP / MXR] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-027-C125   125 µg 350.00 USD Add To Cart
ALX-801-027-C250   250 µg 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: BXP-34
ISOTYPE: Mouse IgG1
CONCENTRATION: ~250µg/ml
FORMULATION: Liquid. In serum free cell culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN: Mitoxanthone resistant BCRP (breast cancer resistance protein; MXR) overexpressing cell line MCF7MR.
SPECIFICITY: Recognizes an internal epitope of human BCRP. Does not cross-react with human P-glycoprotein, MRP1, MRP2 or MRP5.
APPLICATION: Flow Cytometry
Immunocytochemistry: Use 1:20-1:50 dilution on acetone fixed cytospin preparations.
Immunohistochemistry (frozen sections): Use 1:20 dilution of BXP-34 on acetone fixed frozen sections followed by incubation with rabbit anti-mouse IgG and a monoclonal mouse APAAP complex. BXP-34 cannot be used on formaldehyde-fixed paraffin-embedded human tissues and tumors.
Not recommended for Western blot.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
Product Specific Literature References
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines: G.L. Scheffer, et al.; Cancer Res. 60, 2589 (2000) Abstract; Full Text
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues: M. Maliepaard, et al.; Cancer Res. 61, 3458 (2001) Abstract;